论文部分内容阅读
目的研究探讨瑞替普酶和尿激酶静脉溶栓对于急性心肌梗死患者并发症发生情况的影响。方法 100例急性心肌梗死患者,随机为常规组和实验组,各50例。常规组使用尿激酶进行静脉溶栓治疗,实验组使用瑞替普酶进行静脉溶栓治疗,对比两组的并发症发生情况、急性期的病死率以及溶栓治疗2 h内冠状动脉的再通率。结果实验组患者2 h内的再通率84%高于常规组66%,差异具有统计学意义(P<0.05)。实验组患者的并发症发生率16%低于常规组34%,差异具有统计学意义(P<0.05)。实验组患者急性期的病死率6%低于常规组20%,差异具有统计学意义(P<0.05)。结论在急性心肌梗死的治疗中,瑞替普酶的疗效要优于尿激酶,值得在临床上进行推广。
Objective To investigate the influence of reteplase and urokinase intravenous thrombolysis on the complication in patients with acute myocardial infarction. Methods 100 cases of acute myocardial infarction were randomly divided into routine group and experimental group, 50 cases each. The routine group was treated with intravenous thrombolytic therapy with urokinase. The experimental group received intravenous thrombolysis with reteplase. Comparisons were made between the two groups in the incidence of complications, the mortality in acute phase and the recanalization of coronary artery within 2 h after thrombolytic therapy rate. Results The recanalization rate of 84% in the experimental group within 2 h was higher than that in the conventional group (66%), the difference was statistically significant (P <0.05). The incidence of complication in the experimental group was 16% lower than that in the conventional group (34%), the difference was statistically significant (P <0.05). In the experimental group, the mortality rate in acute stage was 6% lower than that in the conventional group (20%), the difference was statistically significant (P <0.05). Conclusion In the treatment of acute myocardial infarction, the effect of reteplase is better than that of urokinase, which is worth to be popularized clinically.